{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:09:49Z","timestamp":1778648989126,"version":"3.51.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["2022-NI-047-00"],"award-info":[{"award-number":["2022-NI-047-00"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-45295-6","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:46:56Z","timestamp":1774432016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design and immunogenicity evaluation of pan-recombinant vaccines based on the consensus sequence of severe acute respiratory syndrome coronavirus-2 spike protein"],"prefix":"10.1038","volume":"16","author":[{"given":"Yoo Jin","family":"Na","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Bee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwangwook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seungyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seo Young","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo-kyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Ju","family":"In","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"45295_CR1","unstructured":"Park, A. Here\u2019s how effective the original vaccines are against omicron. Time (2022). https:\/\/time.com\/6215580\/original-vaccines-effectiveness-against-omicron\/"},{"key":"45295_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41423-023-01116-8","volume":"21","author":"S Cankat","year":"2024","unstructured":"Cankat, S., Demael, M. U. & Swadling, L. In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. Cell. Mol. Immunol. 21, 103\u2013118 (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"45295_CR3","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. A decavalent composite mRNA vaccine against both influenza and COVID-19. mBio 15, e0066824 (2024).","DOI":"10.1128\/mbio.00668-24"},{"key":"45295_CR4","doi-asserted-by":"publisher","first-page":"e2301034","DOI":"10.1002\/advs.202301034","volume":"10","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. A mosaic nanoparticle vaccine elicits potent mucosal immune response with significant cross-protection activity against multiple SARS\u2010CoV\u20102 sublineages. Adv. Sci. (Weinh). 10, e2301034 (2023).","journal-title":"Adv. Sci. (Weinh)"},{"key":"45295_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41541-024-00922-z","volume":"9","author":"G Wang","year":"2024","unstructured":"Wang, G. et al. Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV. npj Vaccines. 9, 133 (2024).","journal-title":"npj Vaccines"},{"key":"45295_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature17200","volume":"531","author":"RN Kirchdoerfer","year":"2016","unstructured":"Kirchdoerfer, R. N. et al. Pre-fusion structure of a human coronavirus spike protein. Nature 531, 118\u2013121 (2016).","journal-title":"Nature"},{"key":"45295_CR7","doi-asserted-by":"publisher","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","volume":"114","author":"J Pallesen","year":"2017","unstructured":"Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. U S A. 114, E7348\u2013E7357 (2017).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"45295_CR8","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N Engl. J. Med."},{"key":"45295_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","volume":"5","author":"R Bos","year":"2020","unstructured":"Bos, R. et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. npj Vaccines. 5, 91 (2020).","journal-title":"npj Vaccines"},{"key":"45295_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"45295_CR11","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"45295_CR12","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"45295_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41594-020-00547-5","volume":"28","author":"RJ Edwards","year":"2021","unstructured":"Edwards, R. J. et al. Cold sensitivity of the SARS-CoV-2 spike ectodomain. Nat. Struct. Mol. Biol. 28, 128\u2013131 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"45295_CR14","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41594-020-0478-5","volume":"27","author":"X Xiong","year":"2020","unstructured":"Xiong, X. et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat. Struct. Mol. Biol. 27, 934\u2013941 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"45295_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.chom.2020.06.010","volume":"28","author":"J Huo","year":"2020","unstructured":"Huo, J. et al. Neutralization of SARS-CoV-2 by destruction of the prefusion spike. Cell. Host Microbe. 28, 445\u2013454e6 (2020).","journal-title":"Cell. Host Microbe"},{"key":"45295_CR16","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41467-020-20501-9","volume":"12","author":"J Ge","year":"2021","unstructured":"Ge, J. et al. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nat. Commun. 12, 250 (2021).","journal-title":"Nat. Commun."},{"key":"45295_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41594-020-0479-4","volume":"27","author":"R Henderson","year":"2020","unstructured":"Henderson, R. et al. Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat. Struct. Mol. Biol. 27, 925\u2013933 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"45295_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622 (2021).","journal-title":"Nature"},{"key":"45295_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","volume":"27","author":"CK Wibmer","year":"2021","unstructured":"Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 27, 622\u2013625 (2021).","journal-title":"Nat. Med."},{"key":"45295_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1126\/science.abe5901","volume":"371","author":"BB Oude Munnink","year":"2021","unstructured":"Oude Munnink, B. B. et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science 371, 172\u2013177 (2021).","journal-title":"Science"},{"key":"45295_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","volume":"3","author":"F Li","year":"2016","unstructured":"Li, F. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3, 237\u2013261 (2016).","journal-title":"Annu. Rev. Virol."},{"key":"45295_CR22","doi-asserted-by":"publisher","first-page":"e00127","DOI":"10.1128\/JVI.00127-20","volume":"94","author":"Y Wan","year":"2020","unstructured":"Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 94, e00127\u2013e00120 (2020).","journal-title":"J. Virol."},{"key":"45295_CR23","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827e19 (2020).","journal-title":"Cell"},{"key":"45295_CR24","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/v14030640","volume":"14","author":"N Magazine","year":"2022","unstructured":"Magazine, N. et al. Mutations and evolution of the SARS-CoV-2 spike protein. Viruses 14, 640 (2022).","journal-title":"Viruses"},{"key":"45295_CR25","doi-asserted-by":"publisher","first-page":"108630","DOI":"10.1016\/j.celrep.2020.108630","volume":"34","author":"SMC Gobeil","year":"2021","unstructured":"Gobeil, S. M. C. et al. D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1\/S2 junction. Cell. Rep. 34, 108630 (2021).","journal-title":"Cell. Rep."},{"key":"45295_CR26","doi-asserted-by":"publisher","first-page":"e2022586118","DOI":"10.1073\/pnas.2022586118","volume":"118","author":"D Benton","year":"2021","unstructured":"Benton, D. et al. (ed, J.) The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2. Proc. Natl. Acad. Sci. U S A 118 e2022586118 (2021).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"45295_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41594-020-0468-7","volume":"27","author":"AG Wrobel","year":"2020","unstructured":"Wrobel, A. G. et al. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Nat. Struct. Mol. Biol. 27, 763\u2013767 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"45295_CR28","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1038\/s41467-020-19808-4","volume":"11","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 11, 6013 (2020).","journal-title":"Nat. Commun."},{"key":"45295_CR29","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41594-021-00652-z","volume":"28","author":"TJ Yang","year":"2021","unstructured":"Yang, T. J. et al. Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function. Nat. Struct. Mol. Biol. 28, 731\u2013739 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"45295_CR30","first-page":"103","volume":"3","author":"DA Ostrov","year":"2021","unstructured":"Ostrov, D. A. Structural consequences of variation in SARS-CoV-2 B.1.1.7. J. Cell. Immunol. 3, 103\u2013108 (2021).","journal-title":"J. Cell. Immunol."},{"key":"45295_CR31","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1111\/febs.15651","volume":"288","author":"M Seyran","year":"2021","unstructured":"Seyran, M. et al. The structural basis of accelerated host cell entry by SARS-CoV\u20102. FEBS J. 288, 5010\u20135020 (2021).","journal-title":"FEBS J."},{"key":"45295_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.bbrc.2004.04.141","volume":"319","author":"J Zhu","year":"2004","unstructured":"Zhu, J. et al. Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem. Biophys. Res. Commun. 319, 283\u2013288 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"45295_CR33","doi-asserted-by":"publisher","first-page":"e106267","DOI":"10.15252\/embj.2020106267","volume":"39","author":"J Buchrieser","year":"2020","unstructured":"Buchrieser, J. et al. Syncytia formation by SARS-CoV-2-infected cells. EMBO J. 39, e106267 (2020).","journal-title":"EMBO J."},{"key":"45295_CR34","doi-asserted-by":"publisher","first-page":"eabi6226","DOI":"10.1126\/science.abi6226","volume":"373","author":"SMC Gobeil","year":"2021","unstructured":"Gobeil, S. M. C. et al. Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. Science 373, eabi6226 (2021).","journal-title":"Science"},{"key":"45295_CR35","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042e21 (2020).","journal-title":"Cell"},{"key":"45295_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442 (2020).","journal-title":"Nature"},{"key":"45295_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.chom.2022.03.018","volume":"30","author":"KE Kistler","year":"2022","unstructured":"Kistler, K. E., Huddleston, J. & Bedford, T. Rapid and parallel adaptive mutations in spike S1 drive clade success in SARS-CoV-2. Cell. Host Microbe. 30, 545\u2013555e4 (2022).","journal-title":"Cell. Host Microbe"},{"key":"45295_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141\u2013154 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"45295_CR39","doi-asserted-by":"crossref","unstructured":"Amanat, F. et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell 184, 3936\u20133948.e10 (2021).","DOI":"10.1016\/j.cell.2021.06.005"},{"key":"45295_CR40","doi-asserted-by":"publisher","first-page":"eabd4250","DOI":"10.1126\/science.abd4250","volume":"370","author":"E Shrock","year":"2020","unstructured":"Shrock, E. et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science 370, eabd4250 (2020).","journal-title":"Science"},{"key":"45295_CR41","doi-asserted-by":"publisher","first-page":"100189","DOI":"10.1016\/j.xcrm.2020.100189","volume":"2","author":"JT Ladner","year":"2021","unstructured":"Ladner, J. T. et al. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell. Rep. Med. 2, 100189 (2021).","journal-title":"Cell. Rep. Med."},{"key":"45295_CR42","doi-asserted-by":"publisher","first-page":"e01991","DOI":"10.1128\/mBio.01991-20","volume":"11","author":"P Nguyen-Contant","year":"2020","unstructured":"Nguyen-Contant, P. et al. S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit. mBio 11, e01991\u2013e01920 (2020).","journal-title":"mBio"},{"key":"45295_CR43","doi-asserted-by":"publisher","first-page":"e151969","DOI":"10.1172\/JCI151969","volume":"131","author":"T Dangi","year":"2021","unstructured":"Dangi, T. et al. Cross-protective immunity following coronavirus vaccination and coronavirus infection. J. Clin. Invest. 131, e151969 (2021).","journal-title":"J. Clin. Invest."},{"key":"45295_CR44","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1128\/JVI.80.2.941-950.2006","volume":"80","author":"KM Lip","year":"2006","unstructured":"Lip, K. M. et al. Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. J. Virol. 80, 941\u2013950 (2006).","journal-title":"J. Virol."},{"key":"45295_CR45","doi-asserted-by":"publisher","first-page":"e50366","DOI":"10.1371\/journal.pone.0050366","volume":"7","author":"HA Elshabrawy","year":"2012","unstructured":"Elshabrawy, H. A., Coughlin, M. M., Baker, S. C. & Prabhakar, B. S. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLOS One. 7, e50366 (2012).","journal-title":"PLOS One"},{"key":"45295_CR46","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bbrc.2005.05.089","volume":"333","author":"J Duan","year":"2005","unstructured":"Duan, J. et al. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem. Biophys. Res. Commun. 333, 186\u2013193 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"45295_CR47","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41467-021-21968-w","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nat. Commun. 12, 1715 (2021).","journal-title":"Nat. Commun."},{"key":"45295_CR48","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.abc6952","volume":"369","author":"X Chi","year":"2020","unstructured":"Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650\u2013655 (2020).","journal-title":"Science"},{"key":"45295_CR49","doi-asserted-by":"crossref","unstructured":"Song, G. et al. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat. Commun. 12, 2938 (2021).","DOI":"10.1038\/s41467-021-23074-3"},{"key":"45295_CR50","doi-asserted-by":"crossref","unstructured":"Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg. Infect. Dis. 26, 1478\u20131488 (2020).","DOI":"10.3201\/eid2607.200841"},{"key":"45295_CR51","doi-asserted-by":"publisher","first-page":"bbac070","DOI":"10.1093\/bib\/bbac070","volume":"23","author":"M Chai","year":"2022","unstructured":"Chai, M. et al. A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domain. Brief. Bioinform. 23, bbac070 (2022).","journal-title":"Brief. Bioinform"},{"key":"45295_CR52","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.immuni.2020.11.015","volume":"53","author":"X Ma","year":"2020","unstructured":"Ma, X. et al. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53, 1315\u20131330e9 (2020).","journal-title":"Immunity"},{"key":"45295_CR53","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1038\/s41467-022-33209-9","volume":"13","author":"C He","year":"2022","unstructured":"He, C. et al. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. Nat. Commun. 13, 5459 (2022).","journal-title":"Nat. Commun."},{"key":"45295_CR54","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41467-024-45404-x","volume":"15","author":"CL Hsieh","year":"2024","unstructured":"Hsieh, C. L. et al. Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge. Nat. Commun. 15, 1553 (2024).","journal-title":"Nat. Commun."},{"key":"45295_CR55","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","volume":"584","author":"N Le Bert","year":"2020","unstructured":"Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457\u2013462 (2020).","journal-title":"Nature"},{"key":"45295_CR56","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41392-023-01422-7","volume":"8","author":"Z Cui","year":"2023","unstructured":"Cui, Z. et al. Comparing T- and B-cell responses to COVID-19 vaccines across varied immune backgrounds. Signal. Transduct. Target. Ther. 8, 179 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"45295_CR57","doi-asserted-by":"publisher","first-page":"1021396","DOI":"10.3389\/fimmu.2022.1021396","volume":"13","author":"G Fedele","year":"2022","unstructured":"Fedele, G. et al. Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study. Front. Immunol. 13, 1021396 (2022).","journal-title":"Front. Immunol."},{"key":"45295_CR58","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1515\/bmc-2018-0007","volume":"9","author":"G Kak","year":"2018","unstructured":"Kak, G., Raza, M. & Tiwari, B. K. Interferon-gamma (IFN-\u03b3): exploring its implications in infectious diseases. Biomol. Concepts. 9, 64\u201379 (2018).","journal-title":"Biomol. Concepts"},{"key":"45295_CR59","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","volume":"54","author":"VJ Costela-Ruiz","year":"2020","unstructured":"Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M. & Ruiz, C. Melguizo-Rodr\u00edguez, L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor. Rev. 54, 62\u201375 (2020).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"45295_CR60","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/sj.embor.7401099","volume":"8","author":"MF Bachmann","year":"2007","unstructured":"Bachmann, M. F. & Oxenius, A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep. 8, 1142\u20131148 (2007).","journal-title":"EMBO Rep."},{"key":"45295_CR61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/978-1-4419-6451-9_3","volume":"684","author":"O Boyman","year":"2010","unstructured":"Boyman, O., Cho, J. H. & Sprent, J. The role of interleukin-2 in memory CD8 cell differentiation. Adv. Exp. Med. Biol. 684, 28\u201341 (2010).","journal-title":"Adv. Exp. Med. Biol."},{"key":"45295_CR62","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.3390\/jcm11175103","volume":"11","author":"G Safont","year":"2022","unstructured":"Safont, G. et al. Measuring T-cell responses against SARS-CoV-2 is of utility for disease and vaccination management. J. Clin. Med. 11, 5103 (2022).","journal-title":"J. Clin. Med."},{"key":"45295_CR63","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/cei\/uxac042","volume":"209","author":"E Phillips","year":"2022","unstructured":"Phillips, E. et al. Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in na\u00efve and convalescent healthcare workers. Clin. Exp. Immunol. 209, 90\u201398 (2022).","journal-title":"Clin. Exp. Immunol."},{"key":"45295_CR64","doi-asserted-by":"publisher","first-page":"e0276241","DOI":"10.1371\/journal.pone.0276241","volume":"17","author":"M Sedegah","year":"2022","unstructured":"Sedegah, M. et al. Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection. PLOS One. 17, e0276241 (2022).","journal-title":"PLOS One"},{"key":"45295_CR65","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41598-024-51505-w","volume":"14","author":"G Safont","year":"2024","unstructured":"Safont, G. et al. Measurement of IFN-\u03b3 and IL-2 for the assessment of the cellular immunity against SARS-CoV-2. Sci. Rep. 14, 1137 (2024).","journal-title":"Sci. Rep."},{"key":"45295_CR66","doi-asserted-by":"publisher","first-page":"eabj1750","DOI":"10.1126\/sciimmunol.abj1750","volume":"6","author":"D Geers","year":"2021","unstructured":"Geers, D. et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci. Immunol. 6, eabj1750 (2021).","journal-title":"Sci. Immunol."},{"key":"45295_CR67","doi-asserted-by":"publisher","first-page":"100562","DOI":"10.1016\/j.xcrm.2022.100562","volume":"3","author":"K Kedzierska","year":"2022","unstructured":"Kedzierska, K. & Thomas, P. G. Count on us: T cells in SARS-CoV-2 infection and vaccination. Cell. Rep. Med. 3, 100562 (2022).","journal-title":"Cell. Rep. Med."},{"key":"45295_CR68","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1038\/s41467-020-19843-1","volume":"11","author":"RAPM Perera","year":"2020","unstructured":"Perera, R. A. P. M. et al. Correlation between viral load and infectivity of SARS-CoV-2. Nat. Commun. 11, 6041 (2020).","journal-title":"Nat. Commun."},{"key":"45295_CR69","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R W\u00f6lfel","year":"2020","unstructured":"W\u00f6lfel, R. et al. Virological assessment of hospitalized patients with COVID-19. Nature 581, 465\u2013469 (2020).","journal-title":"Nature"},{"key":"45295_CR70","first-page":"882123","volume":"13","author":"D Li","year":"2022","unstructured":"Li, D. et al. Persistence of SARS-CoV-2 RNA in tissues and its clinical significance. Front. Microbiol. 13, 882123 (2022).","journal-title":"Front. Microbiol."},{"issue":"2","key":"45295_CR71","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","volume":"5","author":"MA Ramakrishnan","year":"2016","unstructured":"Ramakrishnan, M. A. Determination of 50% endpoint titer using a simple formula. World J. Virol. 5(2), 85\u201386 (2016).","journal-title":"World J. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45295-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45295-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45295-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:18:16Z","timestamp":1778645896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45295-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["45295"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-45295-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7407141\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14930"}}